BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 28597699)

  • 1. Chelation therapy in cardiovascular disease: an update.
    Sultan S; Murarka S; Jahangir A; Mookadam F; Tajik AJ; Jahangir A
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):843-854. PubMed ID: 28597699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chelation therapy to treat atherosclerosis, particularly in diabetes: is it time to reconsider?
    Lamas GA; Ergui I
    Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):927-38. PubMed ID: 27149141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Why the NIH Trial to Assess Chelation Therapy (TACT) should be abandoned.
    Atwood KC; Woeckner E; Baratz RS; Sampson WI
    Medscape J Med; 2008 May; 10(5):115. PubMed ID: 18596934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline characteristics including blood and urine metal levels in the Trial to Assess Chelation Therapy 2 (TACT2).
    Navas-Acien A; Santella RM; Joubert BR; Huang Z; Lokhnygina Y; Ujueta F; Gurvich I; LoIacono NJ; Ravalli F; Ward CD; Jarrett JM; Salazar AL; Boineau R; Jones TLZ; Mark DB; Newman JD; Nathan DM; Anstrom KJ; Lamas GA
    Am Heart J; 2024 Jul; 273():72-82. PubMed ID: 38621575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chelation therapy after the trial to assess chelation therapy: results of a unique trial.
    Avila MD; Escolar E; Lamas GA
    Curr Opin Cardiol; 2014 Sep; 29(5):481-8. PubMed ID: 25023079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heavy Metals, Cardiovascular Disease, and the Unexpected Benefits of Chelation Therapy.
    Lamas GA; Navas-Acien A; Mark DB; Lee KL
    J Am Coll Cardiol; 2016 May; 67(20):2411-2418. PubMed ID: 27199065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chelation trial in patients with cardiovascular disease.
    Yen TH; Yen JS
    Am Heart J; 2023 Feb; 256():1. PubMed ID: 36336079
    [No Abstract]   [Full Text] [Related]  

  • 8. Chelation Therapy in Patients With Cardiovascular Disease: A Systematic Review.
    Ravalli F; Vela Parada X; Ujueta F; Pinotti R; Anstrom KJ; Lamas GA; Navas-Acien A
    J Am Heart Assoc; 2022 Mar; 11(6):e024648. PubMed ID: 35229619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cadmium toxicity and treatment.
    Bernhoft RA
    ScientificWorldJournal; 2013; 2013():394652. PubMed ID: 23844395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: Use and misuse of metal chelation therapy.
    McKay CA
    J Med Toxicol; 2013 Dec; 9(4):301-2. PubMed ID: 24178901
    [No Abstract]   [Full Text] [Related]  

  • 11. A Comprehensive Analysis of the Efficacy of Resveratrol in Atherosclerotic Cardiovascular Disease, Myocardial Infarction and Heart Failure.
    Raj P; Thandapilly SJ; Wigle J; Zieroth S; Netticadan T
    Molecules; 2021 Oct; 26(21):. PubMed ID: 34771008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Environment and cardiovascular health: causes, consequences and opportunities in prevention and treatment].
    Bañeras J; Iglesies-Grau J; Téllez-Plaza M; Arrarte V; Báez-Ferrer N; Benito B; Campuzano Ruiz R; Cecconi A; Domínguez-Rodríguez A; Rodríguez-Sinovas A; Ujueta F; Vozzi C; Lamas GA; Navas-Acién A
    Rev Esp Cardiol; 2022 Dec; 75(12):1050-1058. PubMed ID: 36570815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Commentary on the abuse of metal chelation therapy in patients with autism spectrum disorders.
    Brent J
    J Med Toxicol; 2013 Dec; 9(4):370-2. PubMed ID: 24113859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chelation Therapy as a Cardiovascular Therapeutic Strategy: the Rationale and the Data in Review.
    Mathew RO; Schulman-Marcus J; Nichols EL; Newman JD; Bangalore S; Farkouh M; Sidhu MS
    Cardiovasc Drugs Ther; 2017 Dec; 31(5-6):619-625. PubMed ID: 29129003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chelation therapy to prevent diabetes-associated cardiovascular events.
    Diaz D; Fonseca V; Aude YW; Lamas GA
    Curr Opin Endocrinol Diabetes Obes; 2018 Aug; 25(4):258-266. PubMed ID: 29846236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of high-dose oral multivitamins and minerals in participants not treated with statins in the randomized Trial to Assess Chelation Therapy (TACT).
    Issa OM; Roberts R; Mark DB; Boineau R; Goertz C; Rosenberg Y; Lewis EF; Guarneri E; Drisko J; Magaziner A; Lee KL; Lamas GA
    Am Heart J; 2018 Jan; 195():70-77. PubMed ID: 29224648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced vasculotoxic metal excretion in post-myocardial infarction patients following a single edetate disodium-based infusion.
    Arenas IA; Navas-Acien A; Ergui I; Lamas GA
    Environ Res; 2017 Oct; 158():443-449. PubMed ID: 28689036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of EDTA-based chelation on patients with diabetes and peripheral artery disease in the Trial to Assess Chelation Therapy (TACT).
    Ujueta F; Arenas IA; Escolar E; Diaz D; Boineau R; Mark DB; Golden P; Lindblad L; Kim H; Lee KL; Lamas GA
    J Diabetes Complications; 2019 Jul; 33(7):490-494. PubMed ID: 31101487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of an Omega-3-Carboxylic Acid Formulation in Healthy Male Japanese Subjects: A Phase 1 Single-Blind, Randomized, Placebo-Controlled Trial.
    Noda Y; Nilsson C; Shimada H; Kim H; Lundström T; Yajima T
    Clin Pharmacol Drug Dev; 2018 Feb; 7(2):177-187. PubMed ID: 28597973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chelation therapy for atherosclerotic cardiovascular disease.
    Villarruz-Sulit MV; Forster R; Dans AL; Tan FN; Sulit DV
    Cochrane Database Syst Rev; 2020 May; 5(5):CD002785. PubMed ID: 32367513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.